 | • レポートコード：MRC2Q12-16731 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、B細胞成熟抗原標的療法のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 B細胞成熟抗原標的療法のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 B細胞成熟抗原標的療法の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 B細胞成熟抗原標的療法のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのB細胞成熟抗原標的療法の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のB細胞成熟抗原標的療法の売上および2028年までの予測に焦点を当てています。 B細胞成熟抗原標的療法のグローバル主要企業には、GlaxoSmithKline、Johnson & Johnson、Amgen、Seagen、AbbVie、Novartis、BioTherapeutics、Celgene、Bluebird Bio、Bristol Mayer Squibb、Carsgen Therapeutics、Juno Therapeutics、Cogent Bioscience、CRISPR Therapeutics、Allogene Therapeutics、Harpoon Therapeutics、Poseida Therapeuticsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 B細胞成熟抗原標的療法市場は、タイプとアプリケーションによって区分されます。世界のB細胞成熟抗原標的療法市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 抗体薬物複合体、CAR-T細胞＆二重特異性T細胞エンゲージャー 【アプリケーション別セグメント】 病院、診療所、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - B細胞成熟抗原標的療法製品概要 - タイプ別市場（抗体薬物複合体、CAR-T細胞＆二重特異性T細胞エンゲージャー） - アプリケーション別市場（病院、診療所、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のB細胞成熟抗原標的療法販売量予測2017-2028 - 世界のB細胞成熟抗原標的療法売上予測2017-2028 - B細胞成熟抗原標的療法の地域別販売量 - B細胞成熟抗原標的療法の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別B細胞成熟抗原標的療法販売量 - 主要メーカー別B細胞成熟抗原標的療法売上 - 主要メーカー別B細胞成熟抗原標的療法価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（抗体薬物複合体、CAR-T細胞＆二重特異性T細胞エンゲージャー） - B細胞成熟抗原標的療法のタイプ別販売量 - B細胞成熟抗原標的療法のタイプ別売上 - B細胞成熟抗原標的療法のタイプ別価格 ・アプリケーション別市場規模（病院、診療所、その他） - B細胞成熟抗原標的療法のアプリケーション別販売量 - B細胞成熟抗原標的療法のアプリケーション別売上 - B細胞成熟抗原標的療法のアプリケーション別価格 ・北米市場 - 北米のB細胞成熟抗原標的療法市場規模（タイプ別、アプリケーション別） - 主要国別のB細胞成熟抗原標的療法市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのB細胞成熟抗原標的療法市場規模（タイプ別、アプリケーション別） - 主要国別のB細胞成熟抗原標的療法市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のB細胞成熟抗原標的療法市場規模（タイプ別、アプリケーション別） - 主要国別のB細胞成熟抗原標的療法市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のB細胞成熟抗原標的療法市場規模（タイプ別、アプリケーション別） - 主要国別のB細胞成熟抗原標的療法市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのB細胞成熟抗原標的療法市場規模（タイプ別、アプリケーション別） - 主要国別のB細胞成熟抗原標的療法市場規模（トルコ、サウジアラビア） ・企業情報 GlaxoSmithKline、Johnson & Johnson、Amgen、Seagen、AbbVie、Novartis、BioTherapeutics、Celgene、Bluebird Bio、Bristol Mayer Squibb、Carsgen Therapeutics、Juno Therapeutics、Cogent Bioscience、CRISPR Therapeutics、Allogene Therapeutics、Harpoon Therapeutics、Poseida Therapeutics ・産業チェーン及び販売チャネル分析 - B細胞成熟抗原標的療法の産業チェーン分析 - B細胞成熟抗原標的療法の原材料 - B細胞成熟抗原標的療法の生産プロセス - B細胞成熟抗原標的療法の販売及びマーケティング - B細胞成熟抗原標的療法の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - B細胞成熟抗原標的療法の産業動向 - B細胞成熟抗原標的療法のマーケットドライバー - B細胞成熟抗原標的療法の課題 - B細胞成熟抗原標的療法の阻害要因 ・主な調査結果 |
Market Analysis and Insights: Global B Cell Maturation Antigen Targeted Therapy Market
The global B Cell Maturation Antigen Targeted Therapy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Antibody-Drug Conjugates accounting for % of the B Cell Maturation Antigen Targeted Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China B Cell Maturation Antigen Targeted Therapy market size is valued at US$ million in 2021, while the North America and Europe B Cell Maturation Antigen Targeted Therapy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe B Cell Maturation Antigen Targeted Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global B Cell Maturation Antigen Targeted Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global B Cell Maturation Antigen Targeted Therapy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global B Cell Maturation Antigen Targeted Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global B Cell Maturation Antigen Targeted Therapy market.
Global B Cell Maturation Antigen Targeted Therapy Scope and Market Size
B Cell Maturation Antigen Targeted Therapy market is segmented by players, region (country), by Treatment Method and by Application. Players, stakeholders, and other participants in the global B Cell Maturation Antigen Targeted Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Treatment Method and by Application for the period 2017-2028.
Segment by Treatment Method
Antibody-Drug Conjugates
CAR-T Cells and Bispecific T Cell Engagers
Segment by Application
Hospitals
Clinics
Others
By Company
GlaxoSmithKline
Johnson & Johnson
Amgen
Seagen
AbbVie
Novartis
BioTherapeutics
Celgene
Bluebird Bio
Bristol Mayer Squibb
Carsgen Therapeutics
Juno Therapeutics
Cogent Bioscience
CRISPR Therapeutics
Allogene Therapeutics
Harpoon Therapeutics
Poseida Therapeutics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Treatment Method
1.2.1 Global B Cell Maturation Antigen Targeted Therapy Market Size Growth Rate by Treatment Method, 2017 VS 2021 VS 2028
1.2.2 Antibody-Drug Conjugates
1.2.3 CAR-T Cells and Bispecific T Cell Engagers
1.3 Market by Application
1.3.1 Global B Cell Maturation Antigen Targeted Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global B Cell Maturation Antigen Targeted Therapy Market Perspective (2017-2028)
2.2 B Cell Maturation Antigen Targeted Therapy Growth Trends by Region
2.2.1 B Cell Maturation Antigen Targeted Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 B Cell Maturation Antigen Targeted Therapy Historic Market Size by Region (2017-2022)
2.2.3 B Cell Maturation Antigen Targeted Therapy Forecasted Market Size by Region (2023-2028)
2.3 B Cell Maturation Antigen Targeted Therapy Market Dynamics
2.3.1 B Cell Maturation Antigen Targeted Therapy Industry Trends
2.3.2 B Cell Maturation Antigen Targeted Therapy Market Drivers
2.3.3 B Cell Maturation Antigen Targeted Therapy Market Challenges
2.3.4 B Cell Maturation Antigen Targeted Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top B Cell Maturation Antigen Targeted Therapy Players by Revenue
3.1.1 Global Top B Cell Maturation Antigen Targeted Therapy Players by Revenue (2017-2022)
3.1.2 Global B Cell Maturation Antigen Targeted Therapy Revenue Market Share by Players (2017-2022)
3.2 Global B Cell Maturation Antigen Targeted Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by B Cell Maturation Antigen Targeted Therapy Revenue
3.4 Global B Cell Maturation Antigen Targeted Therapy Market Concentration Ratio
3.4.1 Global B Cell Maturation Antigen Targeted Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by B Cell Maturation Antigen Targeted Therapy Revenue in 2021
3.5 B Cell Maturation Antigen Targeted Therapy Key Players Head office and Area Served
3.6 Key Players B Cell Maturation Antigen Targeted Therapy Product Solution and Service
3.7 Date of Enter into B Cell Maturation Antigen Targeted Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 B Cell Maturation Antigen Targeted Therapy Breakdown Data by Treatment Method
4.1 Global B Cell Maturation Antigen Targeted Therapy Historic Market Size by Treatment Method (2017-2022)
4.2 Global B Cell Maturation Antigen Targeted Therapy Forecasted Market Size by Treatment Method (2023-2028)
5 B Cell Maturation Antigen Targeted Therapy Breakdown Data by Application
5.1 Global B Cell Maturation Antigen Targeted Therapy Historic Market Size by Application (2017-2022)
5.2 Global B Cell Maturation Antigen Targeted Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America B Cell Maturation Antigen Targeted Therapy Market Size (2017-2028)
6.2 North America B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method
6.2.1 North America B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2017-2022)
6.2.2 North America B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2023-2028)
6.2.3 North America B Cell Maturation Antigen Targeted Therapy Market Share by Treatment Method (2017-2028)
6.3 North America B Cell Maturation Antigen Targeted Therapy Market Size by Application
6.3.1 North America B Cell Maturation Antigen Targeted Therapy Market Size by Application (2017-2022)
6.3.2 North America B Cell Maturation Antigen Targeted Therapy Market Size by Application (2023-2028)
6.3.3 North America B Cell Maturation Antigen Targeted Therapy Market Share by Application (2017-2028)
6.4 North America B Cell Maturation Antigen Targeted Therapy Market Size by Country
6.4.1 North America B Cell Maturation Antigen Targeted Therapy Market Size by Country (2017-2022)
6.4.2 North America B Cell Maturation Antigen Targeted Therapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe B Cell Maturation Antigen Targeted Therapy Market Size (2017-2028)
7.2 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method
7.2.1 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2017-2022)
7.2.2 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2023-2028)
7.2.3 Europe B Cell Maturation Antigen Targeted Therapy Market Share by Treatment Method (2017-2028)
7.3 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Application
7.3.1 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Application (2017-2022)
7.3.2 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Application (2023-2028)
7.3.3 Europe B Cell Maturation Antigen Targeted Therapy Market Share by Application (2017-2028)
7.4 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Country
7.4.1 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Country (2017-2022)
7.4.2 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size (2017-2028)
8.2 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method
8.2.1 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2017-2022)
8.2.2 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2023-2028)
8.2.3 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Share by Treatment Method (2017-2028)
8.3 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Application
8.3.1 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Share by Application (2017-2028)
8.4 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Region
8.4.1 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific B Cell Maturation Antigen Targeted Therapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America B Cell Maturation Antigen Targeted Therapy Market Size (2017-2028)
9.2 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method
9.2.1 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2017-2022)
9.2.2 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2023-2028)
9.2.3 Latin America B Cell Maturation Antigen Targeted Therapy Market Share by Treatment Method (2017-2028)
9.3 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Application
9.3.1 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Application (2017-2022)
9.3.2 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Application (2023-2028)
9.3.3 Latin America B Cell Maturation Antigen Targeted Therapy Market Share by Application (2017-2028)
9.4 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Country
9.4.1 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Country (2017-2022)
9.4.2 Latin America B Cell Maturation Antigen Targeted Therapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size (2017-2028)
10.2 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method
10.2.1 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2017-2022)
10.2.2 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Treatment Method (2023-2028)
10.2.3 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Share by Treatment Method (2017-2028)
10.3 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Application
10.3.1 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Share by Application (2017-2028)
10.4 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Country
10.4.1 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline B Cell Maturation Antigen Targeted Therapy Introduction
11.1.4 GlaxoSmithKline Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.1.5 GlaxoSmithKline Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson B Cell Maturation Antigen Targeted Therapy Introduction
11.2.4 Johnson & Johnson Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.2.5 Johnson & Johnson Recent Developments
11.3 Amgen
11.3.1 Amgen Company Details
11.3.2 Amgen Business Overview
11.3.3 Amgen B Cell Maturation Antigen Targeted Therapy Introduction
11.3.4 Amgen Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.3.5 Amgen Recent Developments
11.4 Seagen
11.4.1 Seagen Company Details
11.4.2 Seagen Business Overview
11.4.3 Seagen B Cell Maturation Antigen Targeted Therapy Introduction
11.4.4 Seagen Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.4.5 Seagen Recent Developments
11.5 AbbVie
11.5.1 AbbVie Company Details
11.5.2 AbbVie Business Overview
11.5.3 AbbVie B Cell Maturation Antigen Targeted Therapy Introduction
11.5.4 AbbVie Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.5.5 AbbVie Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis B Cell Maturation Antigen Targeted Therapy Introduction
11.6.4 Novartis Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.6.5 Novartis Recent Developments
11.7 BioTherapeutics
11.7.1 BioTherapeutics Company Details
11.7.2 BioTherapeutics Business Overview
11.7.3 BioTherapeutics B Cell Maturation Antigen Targeted Therapy Introduction
11.7.4 BioTherapeutics Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.7.5 BioTherapeutics Recent Developments
11.8 Celgene
11.8.1 Celgene Company Details
11.8.2 Celgene Business Overview
11.8.3 Celgene B Cell Maturation Antigen Targeted Therapy Introduction
11.8.4 Celgene Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.8.5 Celgene Recent Developments
11.9 Bluebird Bio
11.9.1 Bluebird Bio Company Details
11.9.2 Bluebird Bio Business Overview
11.9.3 Bluebird Bio B Cell Maturation Antigen Targeted Therapy Introduction
11.9.4 Bluebird Bio Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.9.5 Bluebird Bio Recent Developments
11.10 Bristol Mayer Squibb
11.10.1 Bristol Mayer Squibb Company Details
11.10.2 Bristol Mayer Squibb Business Overview
11.10.3 Bristol Mayer Squibb B Cell Maturation Antigen Targeted Therapy Introduction
11.10.4 Bristol Mayer Squibb Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.10.5 Bristol Mayer Squibb Recent Developments
11.11 Carsgen Therapeutics
11.11.1 Carsgen Therapeutics Company Details
11.11.2 Carsgen Therapeutics Business Overview
11.11.3 Carsgen Therapeutics B Cell Maturation Antigen Targeted Therapy Introduction
11.11.4 Carsgen Therapeutics Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.11.5 Carsgen Therapeutics Recent Developments
11.12 Juno Therapeutics
11.12.1 Juno Therapeutics Company Details
11.12.2 Juno Therapeutics Business Overview
11.12.3 Juno Therapeutics B Cell Maturation Antigen Targeted Therapy Introduction
11.12.4 Juno Therapeutics Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.12.5 Juno Therapeutics Recent Developments
11.13 Cogent Bioscience
11.13.1 Cogent Bioscience Company Details
11.13.2 Cogent Bioscience Business Overview
11.13.3 Cogent Bioscience B Cell Maturation Antigen Targeted Therapy Introduction
11.13.4 Cogent Bioscience Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.13.5 Cogent Bioscience Recent Developments
11.14 CRISPR Therapeutics
11.14.1 CRISPR Therapeutics Company Details
11.14.2 CRISPR Therapeutics Business Overview
11.14.3 CRISPR Therapeutics B Cell Maturation Antigen Targeted Therapy Introduction
11.14.4 CRISPR Therapeutics Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.14.5 CRISPR Therapeutics Recent Developments
11.15 Allogene Therapeutics
11.15.1 Allogene Therapeutics Company Details
11.15.2 Allogene Therapeutics Business Overview
11.15.3 Allogene Therapeutics B Cell Maturation Antigen Targeted Therapy Introduction
11.15.4 Allogene Therapeutics Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.15.5 Allogene Therapeutics Recent Developments
11.16 Harpoon Therapeutics
11.16.1 Harpoon Therapeutics Company Details
11.16.2 Harpoon Therapeutics Business Overview
11.16.3 Harpoon Therapeutics B Cell Maturation Antigen Targeted Therapy Introduction
11.16.4 Harpoon Therapeutics Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.16.5 Harpoon Therapeutics Recent Developments
11.17 Poseida Therapeutics
11.17.1 Poseida Therapeutics Company Details
11.17.2 Poseida Therapeutics Business Overview
11.17.3 Poseida Therapeutics B Cell Maturation Antigen Targeted Therapy Introduction
11.17.4 Poseida Therapeutics Revenue in B Cell Maturation Antigen Targeted Therapy Business (2017-2022)
11.17.5 Poseida Therapeutics Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer